Clinical Trials Logo

Filter by:
NCT ID: NCT05848713 Recruiting - Clinical trials for Community-acquired Pneumonia

AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia

ATTACC-CAP
Start date: October 10, 2023
Phase: Phase 3
Study type: Interventional

This is an international, open-label, stratified randomized controlled trial with Bayesian adaptive stopping rules to compare the effects of therapeutic-dose heparin vs. usual care pharmacological thromboprophylaxis on outcomes in patients admitted to hospital with community acquired pneumonia (CAP).

NCT ID: NCT05848583 Terminated - Enteral Feeding Clinical Trials

Nutritional Tolerance and Safety of a Tube Feeding Formula

Start date: March 1, 2023
Phase: N/A
Study type: Interventional

This open-label, prospective study will be conducted to assess the nutritional efficacy, safety, and tolerance of a concentrated, enteral formula in medically stable adults, who currently require or will require to be enterally fed.

NCT ID: NCT05847712 Recruiting - Exercise Clinical Trials

Initial Stay Times and Heat Mitigation Controls for Uncompensable Occupational Heat Stress

Start date: June 8, 2023
Phase: N/A
Study type: Interventional

Workplaces rely on upper heat stress limits provided by the American Conference of Governmental Industrial Hygienists (ACGIH) to manage the health and safety of workers in hot environments. This is primarily achieved by interspersing work with rest periods, the length of which is dictated by environmental conditions and work intensity, to maintain core temperature at or below 38.0°C (equivalent to a 1°C increase in body core temperature above resting levels). However, these guidelines employ a "one size fits all" approach to exposure limits that does not consider individual variation between workers. Moreover, they fail to provide direction on the safe, initial stay times before these heat-mitigation controls should be employed (i.e., rest breaks) in conditions exceeding upper heat stress limits. While recent work has generated estimates of the initial stay times for young to older men before heat-mitigation controls are required for moderate-intensity work, this information is limited to a single work bout and does not consider a second work bout preceded by an extended rest period (e.g., lunch) or next day effects. This is a key consideration, as prolonged work in the heat has been shown to cause next-day impairments in heat dissipation in older men. Further, it remains unclear if the application of the prescribed ACGIH work-rest allocations thereafter would alleviate increases in core temperature for the duration of the work period (e.g., start of shift versus post-lunch period). This project will address these knowledge gaps by determining if refinements in initial stay times for moderate-intensity work (represents the average work effort of physically demanding occupations) in the heat (26°C wet-bulb globe temperature) may be required for young and older adults for i) a second work bout that is preceded by an extended rest period such as a lunch break, and ii) a work bout performed on the next day. This includes assessing the efficacy of the prescribed ACGIH work-rest allocations to mitigate increases in core temperature beyond safe limits (>38.0°C, equivalent to a >1°C increase in body core temperature above resting levels) during these work periods. Given the known sex-differences in heat loss that can modulate core temperature regulation during an exercise-heat stress, the investigators will conduct separate analysis to identify modulating effects of biological sex on the initial stay times and effectiveness of the work-rest allocation as a heat-alleviation control.

NCT ID: NCT05847634 Not yet recruiting - ARDS, Human Clinical Trials

Depth of Sedation and Its Impact on Cerebrovascular Reactivity in Acute Respiratory Distress Syndrome: A Pilot Analysis

Start date: June 2024
Phase:
Study type: Observational

Investigation of the feasibility of monitoring processed transcutaneous electroencephalography (EEG), a method of interpreting brain activity, and near-infrared spectroscopy (NIRS), a method of determining levels of tissue oxygenation (StO2) in the brain, for patients with acute respiratory distress syndrome (ARDS) in the ICU.

NCT ID: NCT05847608 Not yet recruiting - Concussion, Mild Clinical Trials

Omega-3 Treatment for Concussion in Adolescents

CONCUSS
Start date: June 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to test omega-3 fatty acid supplementation as a treatment in adolescents with a concussion. The main questions it aims to answer are: - Does supplementing with omega-3 fatty acids improve time to recovery following sport related concussion. - Does supplementing with omega-3 fatty acids improve health related quality of life following concussion. - Does supplementing with omega-3 fatty acids change post-concussion symptoms following concussion. - Does supplementing with omega-3 fatty acids change saliva concentrations of interleukin-6 following concussion. - Does supplementing with omega-3 fatty acids change saliva concentrations of cortisol following concussion. Participants will be randomized to receive either an omega-3 supplement or placebo after they have been diagnosed with a concussion. Researchers will compare the omega-3 supplement group and placebo group to see if omega-3 fatty acids, consumed as a treatment, can improve time to recovery, health related quality of life and symptom burden, and whether omega-3 fatty acids alter interleukin-6 and cortisol concentrations in saliva following a concussion.

NCT ID: NCT05846230 Recruiting - Bronchiectasis Clinical Trials

Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine

Start date: July 21, 2023
Phase: Phase 2
Study type: Interventional

This study is open to adults aged 18 years and older with bronchiectasis. People can join the study if they were previously enrolled in another study with BI 1291583 (1397-0012: Airleafᵀᴹ). The purpose of this study is to find out whether a medicine called BI 1291583 helps people with bronchiectasis, an inflammatory lung condition. The investigators also want to know how well people with this condition can tolerate BI 1291583 in the long term. Participants take a low, medium, or high dose of BI 1291583 as a tablet once a day for up to 1 year. Participants who were taking placebo in the Airleafᵀᴹ study are put into the BI 1291583 dosage groups randomly, which means by chance. Placebo tablets look like BI 1291583 but do not contain any medicine. Participants who were taking BI 1291583 in the Airleafᵀᴹ study continue to take the same dose. Participants visit the study site 9 times and get 4 phone calls from the site staff. During the visits, the doctors collect information on any health problems of the participants. The doctors also check whether BI 1291583 helps reduce the symptoms of bronchiectasis.

NCT ID: NCT05846022 Completed - Neck Pain Clinical Trials

Effectiveness of Dry Needling Shoulder Muscles on a Head Turning Task in Participants Aged 30-50 With Neck Pain

Start date: May 9, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to compare the immediate effects of stimulating shoulder muscles with an acupuncture needle (dry needling) on people from thirty to fifty years old with recurrent neck pain. The main questions this trial aims to answer are does dry needling tight shoulder muscles have an effect on: 1. the ability to turn your head with speed and accuracy, 2. your neck mobility, 3. pain, 4. the tenderness in the muscles, 5. change in your everyday function. Participants will be asked to undergo a dry needling intervention, then participants will be asked to complete measurements before and after the including a pain scale, neck mobility, a functional questionnaire, pressure sensitivity and movement time for a repetitive head turning task. Researchers will compare the dry needling to the sham needling to see if there is a change in the measurements pre- and post-intervention.

NCT ID: NCT05845814 Active, not recruiting - Clinical trials for Metastatic Urothelial Carcinoma

A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)

Start date: June 23, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This study is a substudy being conducted under one pembrolizumab umbrella master study KEYMAKER-U04. The substudy will consist of 2 parts. Part 1 will evaluate the efficacy and safety of coformulated favezelimab/pembrolizumab plus EV and coformulated vibostolimab/pembrolizumab plus EV relative to pembrolizumab plus EV. There will be no comparison of coformulated favezelimab/pembrolizumab plus EV versus coformulated vibostolimab/pembrolizumab plus EV. If ORR and/or DRR are substantially better on coformulated favezelimab/pembrolizumab plus EV and/or coformulated vibostolimab/pembrolizumab plus EV compared with pembrolizumab plus EV, after evaluation of the totality of data, the sponsor might consider Part 2 (expansion) to further characterize the efficacy and safety of the treatment arms under study.

NCT ID: NCT05845125 Not yet recruiting - Shoulder Pain Clinical Trials

Evolution of Post-Stroke Shoulder Pain With a Capsular Pattern With Physiotherapy Alone Versus Coupled With Mild Arthrographic Distension With Cortisone

Start date: May 2023
Phase: Phase 4
Study type: Interventional

The purpose of this study is to assess the efficacy of mild hydraulic distension with intra-articular corticosteroid injection for the treatment of subacute hemiparetic shoulder pain with a capsular pattern of restricted shoulder motion.

NCT ID: NCT05844826 Recruiting - Multiple Sclerosis Clinical Trials

Evaluation of the Microbiome in Multiple Sclerosis

Start date: June 26, 2023
Phase: N/A
Study type: Interventional

To access the small intestinal microbiome and find abnormal microbiome/metabolome signature in luminal fluid samples from small bowel in MS compared to HC that could be used as biomarkers for MS.